Organic NIR-II dyes with ultralong circulation persistence for image-guided delivery and therapy
Nanocarriers hold great promise for the controlled release of therapeutic payloads to target organs/tissues and extended duration of anticancer agents in the bloodstream. However, limited data on their in vivo pharmacokinetics and delivery process hamper clinical applications. Here we report a serie...
Gespeichert in:
Veröffentlicht in: | Journal of controlled release 2022-02, Vol.342, p.157-169 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Nanocarriers hold great promise for the controlled release of therapeutic payloads to target organs/tissues and extended duration of anticancer agents in the bloodstream. However, limited data on their in vivo pharmacokinetics and delivery process hamper clinical applications. Here we report a series of micellar nanocarriers self-assembled from new-generation thiophenthiadiazole (TTD)-based NIR-II fluorophores HLAnP (n = 1–4) for simultaneous bioimaging and drug delivery. The NIR-II HLA4P nanocarrier displays exceptional non-fouling performance, minimal immunogenicity, ultralong blood half-life, and high tumor accumulation even with different administration routes. When used as a drug carrier, HLA4P with encapsulated doxorubicin (DOX) realized accurate tumor targeting and continuous real-time in vivo NIR-II tracking of drug delivery and therapy, showing a sustained release rate, improved therapeutic effect, and diminished cardiotoxicity as compared to free DOX. This study provides a new perspective on the design of dual-functional NIR-II fluorophores for diagnostic and therapeutic applications.
An ultralow fouling NIR-II probe HLA4P self-assembled into micelles with long-circulation persistence and ultrahigh signal-background ratio for routine preoperative tumor assessment and trackable drug delivery. [Display omitted]
•A new TTD-based NIR-II dye (HLA4P) with a high fluorescence QY, exceptional nonfouling performance and low immunogenicity.•HLA4P exhibited ultralong blood circulation, super-contrast ratio and long tumor retention by various injection routes.•HLA4P could be simultaneously used for long-term in vivo NIR-II tracking of drug delivery and therapy.•HLA4P@DOX showed sustained DOX release behavior, enhanced therapeutic effect and diminished toxicity. |
---|---|
ISSN: | 0168-3659 1873-4995 |
DOI: | 10.1016/j.jconrel.2022.01.005 |